EMA Withdrawn: Rebetol (ribavirin) — Merck Sharp and Dohme B.V

View source ↗

Summary

EMA withdrew Rebetol (ribavirin) from the market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Viral Hepatitis

Drugs mentioned

• Rebetol (ribavirin)

Snippet

Status: Withdrawn. Therapeutic area: Hepatitis C, Chronic. MAH: Merck Sharp and Dohme B.V. Decision date: 24/11/2022